

Safety Data Sheet

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION		
Product Name:	Methadone Hydrochloride Oral Concentrate USP CII (Unflavored or Cherry)	
Product Use:	Treatment of Opioid Addiction	
Manufacturer's Name:	VistaPharm, Inc.	
Address:	7265 Ulmerton Road	
	Largo, FL 33771	
Phone Number:	727-530-1633	
In Case	of Emergency Call National Poison Control: 800-222-1222	
2. HAZARDS IDENTIFICATION		
Emergency Overview	Physical State: Liquid solution administered orally.	
	Clear, unflavored solution with 10gm/mL active ingredient.	
	Red, cherry flavored solution with 10mg/mL active ingredient.	
	Odor: No data available.	
	MAA DANIAG.	
	WARNING:	
	Methadone Hydrochloride Oral Concentrate USP CII is an opioid analgesic.	
	May be harmful if swallowed.	
	Accidental ingestion of large amounts may be fatal.	
Primary Route of Entry:	Ingestion	
Trimary Route of Entry.	ingestion	
Potential Health Effects:	Inhalation: Not expected to be an inhalation hazard in final	
	pharmaceutical form.	
	Eye Contact: Not expected to be a hazard to the eye. Contact with eye	
	may cause irritation, burning and redness.	
	Skin Contact: Not expected to be a hazard to the skin. Can cause	
	hypersensitive reactions resulting in rash, redness, itching and	
	inflammation.	
	Ingestion: May be harmful if ingested. Can cause respiratory depression,	
	nausea, vomiting, sedation and dizziness.	
Toxicity Data:	See Section 11.	
Tfftf O	The patential factor and and the Cottle of the course Cottle	
Effects of Overexposure:	The potential for exposure is reduced in finished pharmaceutical form.	
	Overexposure may cause respiratory depression, extreme somnolence	
	progressing toward stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and constricted pupils. Severe overexposure can cause	
	cianning skin, and constricted pupils. Severe overexposure can cause	

Methadone Hydrochloride Oral Concentrate USP CII – Page 2 of 4

	apnea, circulatory collapse, cardiac arrest and death.
Target Organs:	Central nervous system.
3 COMPOSITION / INFOR	MATION ON INGREDIENTS
Composition:	Methadone Hydrochloride (10mg per 1mL) active ingredient
CAS No:	1095-90-5
Chemical Name:	3-heptanone, 6-(dimethylamino)-4,4-diphenyl-, hydrochloride
Chemical Formula:	C ₂₁ H ₂₇ NO •HCl
Molecular Weight:	345.91
Please refer to current pac	kage insert for other components.
4. FIRST AID MEASURES	
Eye Exposure:	Any material that contacts the eye should be washed out immediately with water. Obtain medical attention if symptoms persist.
Skin Exposure:	Wash affected area with soap and water. Remove contaminated clothing and shoes immediately. Obtain medical attention if symptoms occur.
Inhalation:	Should not pose a hazard in the final form. If breathing is difficult, move to fresh air. Obtain medical attention immediately.
Ingestion:	Call a physician or poison control center immediately.
5. FIRE AND EXPLOSION H	IA7APD
Flash Point:	Not determined.
Extinguishing Media:	Use water spray, dry chemical, carbon dioxide, foam or material appropriate for fire in surrounding area.
Fire Fighting Procedures:	Wear full protective clothing and self-contained breathing apparatus.
Hazardous Combustion Products:	Carbon dioxide, carbon monoxide, oxides of nitrogen, hydrogen chloride.
6. ACCIDENTAL RELEASE N	MEASURES
If Material is Spilled or	Use appropriate personal protective equipment (see Section 8). Wipe up
Released:	and containerize spill material in a compatible container. Dispose according to applicable regulations. Incineration of the waste at an approved facility is recommended.
7. HANDLING AND STORA	.GF
Handling:	Observe good industrial hygiene practices.
Storage:	Store at 20° and 25°C (68° to 77°F). Keep container closed tightly and protect from light. Store away from foodstuffs. Store according to DEA regulations.

Methadone Hydrochloride Oral Concentrate USP CII – Page 3 of 4

8. EXPOSURE CONTROLS AND PERSONAL PROTECTION		
OSHA Exposure Limits:	None	
Engineering Controls:	Not required when handling liquid or containers. Good ventilation should	
	be use. Ventilation should be matched to conditions.	
Respiratory Protection:	Not required when handling liquid or containers. NIOSH/MSHA approved	
	respirators for protection should be used if respirators are found to be	
	necessary. Ventilation should be matched to conditions.	
Personal Protection:	Not required when handling final product. If containers are compromised	
	or exposure is likely wear: goggles, lab coat, and gloves.	
Recommended Facilities:	Eye wash, washing facilities	
9. PHYSICAL AND CHEMICA	L PROPERTIES	
Appearance and Odor:	Clear or red liquid solution	
Melting Point (deg. C):	Not determined.	
Boiling Point (deg. C):	Not determined.	
Solubility:	Soluble	
pH:	Not determined.	
10. STABILITY AND REACTIVE	/ITY	
Chemical Stability:	Yes	
Conditions to Avoid:	Excessive heat or cold, light	
Incompatibility:	Oxidizing agents, alkalis	
Hazardous Decomposition:	Oxides of carbon, oxides of nitrogen, hydrogen chloride	
Hazardous Polymerization:	No	
11. TOXICOLOGICAL INFOR	MATION	
Acute Toxicity:		
Active Ingredient:		
Oral LD50 (rat):	30 mg/kg	
Oral LD50 (mouse):	124 mg/kg	
Carcinogenicity:	Not listed as a carcinogen by NTP, IARC Monographs or OSHA	
12. ECOLOGICAL INFORMA		
Environmental Effects :	Not determined.	
13. WASTE DISPOSAL INFO	RMATION	
Waste Disposal	Drug Enforcement Administration controlled substances must be	
Considerations:	destroyed following DEA Guidelines for witness destruction of the product	
	beyond reclamation. Disposal by incineration is recommended.	
At Home:	Discard away from children's reach.	
14. TRANSPORTATION INFORMATION		
This product is authorized as	s exempt, therefore is not subject to regulations for the safe transport of	

Methadone Hydrochloride Oral Concentrate USP CII – Page 4 of 4

hazardous chemicals. 15. REGULATORY INFORMATION		
FDA:	Methadone Hydrochloride CII is an approved prescription medication.	
Inventory Status:	The material is not listed on the US TSCA Inventory. Therefore, it can only be used for TSCA exempt purposes such as R&D or drug use. This material is not listed on the DSL Inventory but is exempt.	
16. DISCLAIMER		
The above information has been obtained from a number of sources and its accuracy cannot be guaranteed. It is the user's responsibility to evaluate the information and use it in a prudent manner for it particular purpose. VistaPharm, Inc. assumes no responsibility for the use of this information.		
Date: May 2015		
SEE CURRENT PACKAGE INSERT FOR FURTHER INFORMATION		